Trials / Completed
CompletedNCT01092403
Safety, Tolerability and Clinical Activity of ASM-024 in Subjects With Mild Allergic Asthma
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of ASM-024 Administered by Inhalation Once Daily to Subjects With Mild Allergic Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Asmacure Ltée · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The study will assess the safety, tolerability and clinical activity of ASM-024 in subjects with mild allergic asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASM-024 | ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation |
| DRUG | Placebo | Placebo once daily by inhalation |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2011-12-01
- Completion
- 2012-01-01
- First posted
- 2010-03-25
- Last updated
- 2012-01-26
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01092403. Inclusion in this directory is not an endorsement.